Search results for " STEATOSIS"

showing 3 items of 63 documents

Differences between current clinical guidelines for screening, diagnosis and management of non-alcoholic fatty liver disease and real-world practice:…

2021

International audience; INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and is associated with obesity and metabolic comorbidities. Liver steatosis can progress to nonalcoholic steatohepatitis (NASH) exhibiting a relevant risk of fibrosis and ultimately liver failure. To date, no approved treatment for NASH to reduce its clinical and humanistic burden has been developed. AREAS COVERED: We undertook a literature review to identify English language, national and international clinical guidelines for NAFLD regarding diagnosis, assessment and management, and determined their points of agreement and difference. Additionally, we investigated published liter…

nonalcoholic fatty liver diseaseNonalcoholic steatohepatitismedicine.medical_specialtyliterature review[SDV]Life Sciences [q-bio]Liver fibrosisdigestive systemGastroenterologyDiagnosis DifferentialLiver diseasereal-world practiceLiver steatosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansMass Screeningnonalcoholic steatohepatitisliver fibrosisHepatologybusiness.industryGastroenterologynutritional and metabolic diseasesfood and beveragesmedicine.diseaseObesitydigestive system diseases[SDV] Life Sciences [q-bio]clinical guidelinesPractice Guidelines as Topicbusiness
researchProduct

IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION

2019

Background: Background:Nonalcoholic fatty liver (NAFL) is a major cause of liver disease worldwide leading also to a higher risk of cardiovascular events. We aimed to evaluate the impact of fatty liver and fibrosis on cardiovascular risk factors in a general population. Methods: 604 subjects included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study were recruited. Steatosis (CAP >288 dB/m) and fibrosis (> 8.7 KPa by M and > 7.2 KPa by XL probe) were assessed with FibroScan Cardiovascular risk was evaluated by the Atherosclerotic Cardiovascular Disease (ASCVD) risk estimator and de ned low if <5%, borderline if 5%-7 4%, intermediate if 7-9% a…

obesity diabetes steatosis ABCD study fatty liver disease
researchProduct

Effet anti-obésité des CLA : mythe ou réalité ?

2005

Conjugated linoleic acids (CLA) are positional and geometric isomers of linoleic acid. Inclusion of CLA in the diet provokes a rapid and marked decrease in body weight gain and adiposity in mice leading to a lipoatrophic syndrome. However, CLA supplementation raised fasting blood glucose and insulin concentrations and was associated with severe insulin resistance and liversteatosis. Conflicting results have been reported with regard to reduction of fat mass in humans. We have reviewed the publish literature regarding the effect of CLA on body composition in humans and animal models. These studies indicate that t10-c12 was the isomer that reduced adipose fat storage, however it also increase…

obesitymedicine.medical_specialtymedicine.medical_treatmentConjugated linoleic acidAdipose tissuelcsh:TP670-699BiologyadipocyteBiochemistryliver steatosischemistry.chemical_compoundlipoatrophic diabetesInsulin resistanceInternal medicineAdipocytemedicinelipogenesisUnsaturated fatty acidLipoatrophic diabetesintegumentary systemInsulinFatty liverfood and beveragesmedicine.diseaseEndocrinologychemistrylipids (amino acids peptides and proteins)lcsh:Oils fats and waxesFood ScienceOléagineux, Corps gras, Lipides
researchProduct